{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:03:54Z","timestamp":1794128634550,"version":"4.8.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100022336","name":"Esperion Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ahj.2024.06.012","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T02:34:37Z","timestamp":1720233277000},"page":"107-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Achievement of LDL-C &lt;55 mg\/dL among US adults: Findings from the cvMOBIUS2 registry"],"prefix":"10.1016","volume":"279","author":[{"given":"Ann Marie","family":"Navar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Shrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laine E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Allred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna M.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Chrischilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafeesa","family":"Dhalwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Effron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Hayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laney K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Kalich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"W\u00f3jcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.06.012_bib0001","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.06.012_bib0002","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-Cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology solution set oversight committee","volume":"80","author":"Writing","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.06.012_bib0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.06.012_bib0004","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/CIRCULATIONAHA.121.056536","article-title":"Cardiovascular benefit of lowering low-density lipoprotein cholesterol below 40 mg\/dL","volume":"144","author":"Marston","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.06.012_bib0005","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.06.012_bib0006","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.06.012_bib0007","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.06.012_bib0008","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.06.012_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.06.012_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100336","article-title":"Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 update","volume":"10","author":"Gu","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.ahj.2024.06.012_bib0011","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","article-title":"LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals","volume":"134","author":"Underberg","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.ahj.2024.06.012_bib0012","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ahj.2017.08.005","article-title":"Lipid management in contemporary community practice: results from the provider assessment of lipid management (PALM) registry","volume":"193","author":"Navar","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.06.012_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex differences in the use of statins in community practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2024.06.012_bib0014","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.jacc.2018.02.032","article-title":"Sex differences in high-intensity statin use following myocardial infarction in the United States","volume":"71","author":"Peters","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.06.012_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1047","article-title":"Assessment of sex disparities in nonacceptance of statin therapy and low-density lipoprotein cholesterol levels among patients at high cardiovascular risk","volume":"6","author":"Brown","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ahj.2024.06.012_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104514","article-title":"Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: need for customisation strategies","volume":"155","author":"Olmastroni","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ahj.2024.06.012_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100496","article-title":"Natural language processing to identify reasons for sex disparity in statin prescriptions","volume":"14","author":"Witting","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.ahj.2024.06.012_bib0018","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamacardio.2018.1511","article-title":"Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the patient and provider assessment of lipid management registry","volume":"3","author":"Nanna","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.06.012_bib0019","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-Intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.06.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009251","article-title":"Measurement of low-density lipoprotein cholesterol levels in primary and secondary prevention patients: insights from the PALM registry","volume":"7","author":"Lowenstern","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2024.06.012_bib0021","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archinternmed.2007.124","article-title":"Better outcomes for patients treated at hospitals that participate in clinical trials","volume":"168","author":"Majumdar","year":"2008","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.ahj.2024.06.012_bib0022","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jacc.2021.11.042","article-title":"Discordance between standard equations for determination of LDL cholesterol in patients with atherosclerosis","volume":"79","author":"Sajja","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324001650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324001650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:09:49Z","timestamp":1733130589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324001650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"alternative-id":["S0002870324001650"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.06.012","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achievement of LDL-C <55 mg\/dL among US adults: Findings from the cvMOBIUS2 registry","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.08.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}